**Estimated Proportion of Participants with New Use of Lipid-Lowering Medication through Week 96 (Adjusted for Age and Baseline Weight)**

|  | Weight Gain Group | | | |  |
| --- | --- | --- | --- | --- | --- |
|  | Low: <10% | | High: ≥10% | |  |
| Treatment Group | n | Estimated Percent (95% CI) | n | Estimated Percent (95% CI) | Difference  (Low - High) |
| Doravirine | 556 | 2.9 (1.4, 4.3) | 89 | 0.8 (0.0, 7.7) † | 2.0 (-5.5, 9.5) |
| Darunavir | 216 | 1.4 (0.0, 4.2) † | 42 | 4.6 (0.0, 13.2) † | -3.3 (-12.2, 5.7) |
| Efavirenz | 302 | 6.8 (4.0, 9.5) | 50 | 0.0 (0.0, 94.5) † | 9.9 (-87.8, 100.0) † |
| † For proportions, the estimate and lower bound are truncated at 0 and upper bound at 100. For differences, the estimate and lower bound are truncated at -100 and upper bound at 100.  Subjects with missing weight change are not included in the analysis.  Use of medication of interest is based on subject’s concomitant medication data post baseline. Subjects are considered as having used the medication of interest in a visit if they did not use the medication at baseline but used the medication post baseline and the interval of use, from first use to last use, falls into the visit. Subjects who used the medications of interest before the study were excluded. | | | | | |